RAD-140 [Discontinued] by Swoll Mafia

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Athletic performance. Although there is interest in using oral testolone for athletic performance, there is insufficient reliable information about the clinical effects of testolone for this purpose.
• Breast cancer. Although there is interest in using oral testolone for breast cancer, there is insufficient reliable information about the clinical effects of testolone for this condition. Details: In a small, dose-finding clinical study in postmenopausal patients with an advanced form of ER+/HER2- breast cancer taking testolone for a median of about 8 weeks, there was one partial response (5.9%) and nine (52.9%) patients with stable disease. Doses were 50 mg, 100 mg, or 150 mg daily. In patients taking 100 mg daily, median progression-free survival was 2.2 months and a clinical benefit was observed in 18.2% of patients (108159).
• Cachexia. Although there is interest in using oral testolone for cachexia, there is insufficient reliable information about the clinical effects of testolone for this condition.
• Muscle strength. Although there is interest in using oral testolone for muscle strength, there is insufficient reliable information about the clinical effects of testolone for this purpose.
• Muscular dystrophy. Although there is interest in using oral testolone for muscular dystrophy, there is insufficient reliable information about the clinical effects of testolone for this condition.
• Osteoporosis. Although there is interest in using oral testolone for osteoporosis, there is insufficient reliable information about the clinical effects of testolone for this condition.
• Sarcopenia. Although there is interest in using oral testolone for sarcopenia, there is insufficient reliable information about the clinical effects of testolone for this condition.
• Urinary incontinence. Although there is interest in using oral testolone for urinary incontinence, there is insufficient reliable information about the clinical effects of testolone for this condition. More evidence is needed to rate testolone for these uses.

(Read more about TESTOLONE)

POSSIBLY UNSAFE ...when used orally. There are case reports of acute myocarditis and liver injury associated with use of testolone (108160,108161). Dietary supplements containing selective androgen receptor modulators (SARMs), such as testolone, have been associated with reports of liver toxicity and increased risk of myocardial infarction and stroke (94879,94880,94881). The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing SARMs are dangerous (91094).

PREGNANCY AND LACTATION: POSSIBLY UNSAFE
when used orally. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing selective androgen receptor modulators (SARMs) are dangerous (91094). Avoid using.

(Read more about TESTOLONE)

HEPATOTOXIC DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = High •  Occurrence = Possible •  Level of Evidence = B Theoretically, concomitant use might have additive hepatotoxic effects.  Details In a case report, a 52-year-old male was diagnosed with liver injury thought to be related to the use of products containing testolone (108160). Also, elevated liver enzymes were commonly reported in a dose escalation study of testolone (108159).

(Read more about TESTOLONE)

General ...Testolone is possibly unsafe.
Most Common Adverse Effects:
Decreased appetite, dehydration, elevated liver enzymes, vomiting, and weight loss.
Serious Adverse Effects (Rare):
Acute myocarditis, hypophosphatemia, and liver injury.

Cardiovascular ...Acute myocarditis presumably associated with testolone has been reported in a 32-year-old male who used the product for athletic performance enhancement. The patient presented with shortness of breath and a mild fever, with elevations in troponin I, B-type natriuretic peptide, erythrocyte sedimentation rate, C-reactive protein, and D-dimer and received treatment with aspirin, atorvastatin, carvedilol, and furosemide, with a heparin drip (108161).
The US Food and Drug Administration (FDA) has warned that supplements containing SARMs, such as testolone, have been associated with myocardial infarction and stroke (94879,94880,94881).
One patient in a small study experienced mild palpitations that were thought to be possibly related to the use of oral testolone 100 mg daily for about 8 weeks (108159).

Dermatologic ...Orally, abnormal hair growth and acne occurred in one patient each and were related or possibly related to the use of oral testolone 50 mg or 100 mg daily for about 8 weeks (108159).

Gastrointestinal ...Orally, vomiting and decreased appetite were reported to be some of the most common adverse effects in a dose escalation study of testolone 50-150 mg daily for about 8 weeks (108159).

Hematologic ...Orally, hypophosphatemia occurred in about 23% of patients in a dose escalation study of testolone 50-150 mg daily for about 8 weeks (108159).

Hepatic ...A dose escalation study of testolone 50-150 mg daily for about 8 weeks found that the most common treatment-emergent adverse events included moderate elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin (108159). In one case report, a 52-year-old male was diagnosed with liver injury thought to be related to the use of testolone 20 mg daily (Alpha Bolic) for 4 weeks and then testolone 15 mg daily with ligandrol 10 mg daily (Alpha Elite) for 3 weeks. The patient presented with elevated liver enzymes, jaundice, pruritus, diarrhea, and upper right quadrant pain; liver enzymes were significantly improved 3 months after cessation of the supplements and alcohol intake (108160). It is unclear if this case of liver injury was due to testolone, ligandrol, the combination, unapproved substance(s) not reported on the label, and/or alcohol use. The U.S. Food and Drug Administration (FDA) has warned that supplements containing SARMs, such as testolone, have been associated with liver toxicity (94879,94880,94881).

Other ...A dose escalation study of testolone 50-150 mg daily for about 8 weeks found that some of the most common treatment-emergent adverse events included dehydration and decreased weight (108159). Conversely, one patient in a clinical study experienced weight gain, which was thought to be related or possibly related to the use of oral testolone 100 mg daily for about 8 weeks (108159).

(Read more about TESTOLONE)